IperionX tops FY2026 director fee cap by US$119K
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
IperionX Limited (IPX) disclosed a breach of ASX Listing Rule 10.17A after aggregate non-executive director cash fees exceeded the shareholder-approved US$300,000 annual pool by US$13,804 in FY2024, US$38,796 in FY2025 and US$119,007 in FY2026. The company attributed the failure to seek approval for a higher pool to administrative oversight.
FY2027 gross NED cash compensation was reduced to US$300,000, including superannuation, effective July 1, 2026. Affected directors agreed to repay historical excesses through offsets; net FY2027 NED cash fees are currently expected to total US$128,392. IperionX is seeking shareholder approval to raise the pool to US$700,000; if approved, net FY2027 fees would total US$288,392. The company also says it added quarterly checks against the fee cap.
Key Figures
Key Terms
ASX Listing Rule 10.17A regulatory
aggregate annual cash fee pool financial
superannuation financial
repayment offsets financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did IperionX’s non-executive director fees exceed the approved pool by?
How much does IperionX expect to pay its non-executive directors in FY2027?
AI-generated analysis. How Rhea-AI works. Not financial advice.
